CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression

被引:83
|
作者
Reynes, J
Portales, P
Segondy, M
Baillat, V
André, P
Avinens, O
Picot, MC
Clot, J
Eliaou, JF
Corbeau, P
机构
[1] Hop St Eloi, Immunol Lab, F-34295 Montpellier 5, France
[2] Hop St Eloi, Virol Lab, F-34295 Montpellier, France
[3] Hop Gui De Chauliac, Serv Malad Infect & Trop, Montpellier, France
[4] Hop Arnaud Villeneuve, Dept Med Informat, Montpellier, France
[5] Inst Genet Humaine, Montpellier, France
关键词
AIDS/HIV; CCR5; CD4 cell slope; chemokine receptor; long-term non-progressor; prognostic factor; T lymphocytes;
D O I
10.1097/00002030-200109070-00004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective and design: We have recently shown that the number of CCR5 molecules at the surface of peripheral blood CD4 T cells (CCR5 density) correlates with the viral RNA plasma level in HIV-1-infected individuals. As viral load is a strong predictor of outcome in HIV infection, the present study examines the correlation between CCR5 density and HIV-1 disease progression. Methods: Using a quantitative flow cytometry assay, we measured CCR5 density in HIV-1-infected adults and control healthy volunteers. The CCR5 genotype (presence of a Delta 32 allele) was also determined. Results: CCR5 density was stable over time on non-activated, HLA-DR(-)CD4 T cells of infected individuals. In a study cohort of 25 patients, asymptomtic and non-treated, we observed a correlation between CCR5 density on HLA-DR-CD4 T cells and the CD4 T cell slope (P = 0.026), which was independent of the presence or absence of the Delta 32CCR5 deletion. In particular, slow progressors expressed lower CCR5 densities than non-slow progressors (P = 0.004) and non-infected control subjects (P = 0.002). Conclusion: These results are compatible with the hypothesis that CCR5 density, which is a key factor of HIV-1 infectability, determines in-vivo HIV production, and thereby the rate of CD4 cell decline. Consequently, CCR5 density quantitation could be a new valuable prognostic tool in HIV-1 infection. Moreover, these data emphasize the therapeutic potential of treatments that reduce functional CCR5 density. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:1627 / 1634
页数:8
相关论文
共 50 条
  • [1] The efficiency of R5 HIV-1 infection is determined by CD4 T-cell surface CCR5 density through Gαi-protein signalling
    Lin, Yea-Lih
    Mettling, Clement
    Portales, Pierre
    Reant, Brigitte
    Robert-Hebmann, Veronique
    Reynes, Jacques
    Clot, Jacques
    Corbeau, Pierre
    AIDS, 2006, 20 (10) : 1369 - 1377
  • [2] CCR5 interaction with HIV-1 Env contributes to Env-induced depletion of CD4 T cells in vitro and in vivo
    Tsao, Li-Chung
    Guo, Haitao
    Jeffrey, Jerry
    Hoxie, James A.
    Su, Lishan
    RETROVIROLOGY, 2016, 13
  • [3] Constitutive association of cell surface CCR5 and CXCR4 in the presence of CD4
    Wang, JH
    Alvarez, R
    Roderiquez, G
    Guan, E
    Norcross, MA
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2004, 93 (04) : 753 - 760
  • [4] The Effects of the Recombinant CCR5 T4 Lysozyme Fusion Protein on HIV-1 Infection
    Jin, Qingwen
    Chen, Hong
    Wang, Xingxia
    Zhao, Liandong
    Xu, Qingchen
    Wang, Huijuan
    Li, Guanyu
    Yang, Xiaofan
    Ma, Hongming
    Wu, Haoquan
    Ji, Xiaohui
    PLOS ONE, 2015, 10 (07):
  • [5] Genetic polymorphism of CCR5 gene and HIV disease:: the heterozygous (CCR5/Δccr5) genotype is neither essential nor sufficient for protection against disease progression
    Morawetz, RA
    Rizzardi, GP
    Glauser, D
    Rutschmann, O
    Hirschel, B
    Perrin, L
    Opravil, M
    Flepp, M
    von Overbeck, J
    Glauser, MP
    Ghezzi, S
    Vicenzi, E
    Poli, G
    Lazzarin, A
    Pantaleo, G
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (12) : 3223 - 3227
  • [6] The strength of the chemotactic response to a CCR5 binding chemokine is determined by the level of cell surface CCR5 density
    Desmetz, Caroline
    Lin, Yea-Lih
    Mettling, Clement
    Portales, Pierre
    Rabesandratana, Herisoa
    Clot, Jacques
    Corbeau, Pierre
    IMMUNOLOGY, 2006, 119 (04) : 551 - 561
  • [7] Coreceptor choice and T cell depletion by R5, X4, and R5X4 HIV-1 variants in CCR5-deficient (CCR5Δ32) and normal human lymphoid tissue
    Malkevitch, N
    McDermott, DH
    Yi, YJ
    Grivel, JC
    Schols, D
    De Clercq, E
    Murphy, PM
    Glushakova, S
    Collman, RG
    Margolis, L
    VIROLOGY, 2001, 281 (02) : 239 - 247
  • [8] Peripheral blood T4 cell surface CCR5 density as a marker of activity in rheumatoid arthritis treated with anti-CD20 monoclonal antibody
    Portales, Pierre
    Fabre, Sylvie
    Vincent, Thierry
    Desmetz, Caroline
    Reant, Brigitte
    Noel, Daniele
    Clot, Jacques
    Jorgensen, Christian
    Corbeau, Pierre
    IMMUNOLOGY, 2009, 128 (01) : e738 - e745
  • [9] T-cell surface CCR5 density is not correlated with hepatitis severity in hepatitis C virus/HIV-coinfected individuals - Implications for the therapeutic use of CCR5 antagonists
    Vincent, T
    Portales, P
    Baillat, V
    de Boever, CM
    Le Moing, V
    Vidal, M
    Ducos, J
    Clot, J
    Reynes, J
    Corbeau, P
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 38 (03) : 305 - 309
  • [10] Allosteric regulation of CCR5 by guanine nucleotides and HIV-1 envelope
    Staudinger, R
    Wang, XH
    Bandrés, JC
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 286 (01) : 41 - 47